A Study of SHR-4394 Injection in Subjects With Prostate Cancer

Exclusion Criteria

• •1. Received systemic anticancer treatments or clinical investigational drugs 4 weeks prior to the initiation of the study treatment;
• •2. Unresolved to CTCAE 5.0\>=grade 2 toxicities from previous anticancer therapy;
• •3. Meningeal metastasis history or clinical symptoms of central nervous system metastasis;
• •4. Uncontrollable tumor-related pain;
• •5. Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion with clinical symptoms;
• •6. Other serious concomitant disease;
• •7. Previous or co-existing malignancies;
• •8. History of severe hypersensitivity reactions to either the drug substances or inactive ingredients of SHR-4394;
• •9. Active hepatitis B or active hepatitis C;
• •10. Other inappropriate situation considered by the investigator.